JO3362B1 - الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان - Google Patents

الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان

Info

Publication number
JO3362B1
JO3362B1 JOP/2014/0365A JOP20140365A JO3362B1 JO 3362 B1 JO3362 B1 JO 3362B1 JO P20140365 A JOP20140365 A JO P20140365A JO 3362 B1 JO3362 B1 JO 3362B1
Authority
JO
Jordan
Prior art keywords
cancer
immunotherapy
cells
cryopreservation
immunotherapy against
Prior art date
Application number
JOP/2014/0365A
Other languages
English (en)
Inventor
Moserova Irena
Truxova Iva
FUCIKOVA Jitka
Rozkova Daniela
Spisek Radek
Pokorna Katerina
Koci Lenka
Original Assignee
Sotio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio As filed Critical Sotio As
Application granted granted Critical
Publication of JO3362B1 publication Critical patent/JO3362B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0278—Physical preservation processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتم في هذه الوثيقة وصف طريقة يمكن الاعتماد عليها لإعداد لقاح فعال مفيد لعلاج مناعي تتضمن الطريقة خطوة الحفظ بالتبريد لجمهرة خلايا لتخضع لموت الخلايا المناعي، واستخدام مثل هذه الخلايا لتنشيط الخلايا الجذعية لاستخدامها في العلاج المناعي. في تجسيد معين، تتضمن الطريقة الحفظ بالتبريد لخلايا سرطانية لتخضع لموت خلايا، والتي يمكن استخدامها لإعداد تركيبة دوائية لعلاج مناعي ضد السرطان.
JOP/2014/0365A 2013-12-27 2014-12-17 الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان JO3362B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/142,448 US9562219B2 (en) 2013-12-27 2013-12-27 Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

Publications (1)

Publication Number Publication Date
JO3362B1 true JO3362B1 (ar) 2019-03-13

Family

ID=52292898

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0365A JO3362B1 (ar) 2013-12-27 2014-12-17 الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان

Country Status (9)

Country Link
US (5) US9562219B2 (ar)
KR (1) KR20160113611A (ar)
AR (1) AR100666A1 (ar)
AU (1) AU2014372723A1 (ar)
CA (1) CA2935126A1 (ar)
JO (1) JO3362B1 (ar)
MX (1) MX2016008432A (ar)
TW (1) TW201528948A (ar)
WO (1) WO2015097037A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
JP2019517537A (ja) * 2016-06-06 2019-06-24 ソティオ エイ． エス． がん免疫療法
KR102256337B1 (ko) * 2017-10-17 2021-05-26 (주)노터스생명과학 조직이식을 위한 세포배양액을 포함하는 면역억제제
KR20200116112A (ko) 2018-01-25 2020-10-08 소티오 에이.에스. 화학요법에 순차적인 수지상 세포 백신접종
CA3087823A1 (en) 2018-01-25 2019-08-01 SOTIO a.s. Dendritic cell vaccination in parallel to chemotherapy
WO2020187975A1 (en) 2019-03-19 2020-09-24 SOTIO a.s. Patient selection for treatment with dendritic cell vaccination
JP7340240B2 (ja) * 2019-08-26 2023-09-07 学校法人関西医科大学 細胞又は組織にアポトーシスを誘導する方法
WO2021113328A1 (en) 2019-12-03 2021-06-10 Neuvogen, Inc. Tumor cell vaccines
EP4232078A1 (en) * 2020-10-20 2023-08-30 The Regents of The University of California Attenuated cancer cells and methods related thereto
WO2022171792A1 (en) 2021-02-12 2022-08-18 Sctbio A.S. Patient selection for treatment with dendritic cell vaccination
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602709B1 (en) 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
AU757443B2 (en) * 1998-05-11 2003-02-20 I.D.M. Immuno-Designed Molecules New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
WO2006047515A2 (en) 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
WO2006095330A2 (en) 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
BR112012020303A2 (pt) 2010-02-19 2019-09-24 Cadila Pharmaceuticals Ltd "composição estável de células mortas com propriedades imunogênicas substancialmente retidas, e, processo e método de preparação da composição."
US20130011438A1 (en) 2011-07-05 2013-01-10 SOTIO a.s. Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells
EP2543386A1 (en) 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

Also Published As

Publication number Publication date
KR20160113611A (ko) 2016-09-30
AR100666A1 (es) 2016-10-26
US9895430B2 (en) 2018-02-20
US20180125956A1 (en) 2018-05-10
US9562219B2 (en) 2017-02-07
TW201528948A (zh) 2015-08-01
US20190070278A1 (en) 2019-03-07
CA2935126A1 (en) 2015-07-02
WO2015097037A1 (en) 2015-07-02
US20150184130A1 (en) 2015-07-02
US10155033B2 (en) 2018-12-18
US20170232086A1 (en) 2017-08-17
MX2016008432A (es) 2016-10-28
US20200147191A1 (en) 2020-05-14
US10561717B2 (en) 2020-02-18
AU2014372723A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
JO3362B1 (ar) الحفظ بالتبريد لخلايا سرطان الموت الخلوي المبرمج للاستعمال في العلاج المناعي ضد السرطان
PH12017500803A1 (en) Anti-pd-1 antibodies
EP3070163A4 (en) Method for preparing induced pluripotent stem cell, composition used in method, and uses thereof
EP3019596A4 (en) Compositions and methods for reprograming non- pluripotent cells into pluripotent stem cells
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
DK201300194U1 (da) Aluminiumhydroxidkoncentrat, fortrinsvis til anvendelse i fremstillingen af en vaccine
PH12015502535B1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
IN2015MN00038A (ar)
EP2998322A4 (en) EPITOPE BASED VACCINE FOR LOW IMMUNOGENICITY PROTEIN AND METHOD FOR PREPARING AND USING SAME
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
HK1204859A1 (en) Planting method of part-open greenhouse for peach tree in low latitude and high elevation region
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
MX2015009938A (es) Macromoleculas en forma de estrella tolerantes a las sales.
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
EP2964789A4 (en) ISOTHERMIC NUCLEIC ACID AMPLIFICATION AND LIBRARY GENERATION AND CLONING GENERATION IN SEQUENCING
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
PH12015501187A1 (en) Method for synchronizing time of insemination in gilts
IL287488A (en) Methods for the development and use of minimally polarized microaggregate cell units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells
AR089995A1 (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas
CL2015001539A1 (es) Método para producir células dendríticas tolerogénicas autólogas (toldcs) con antígenos específicos; toldcs obtenidas por dicho método; y su uso en la preparación de un medicamento útil para el tratamiento de lupus eritematoso sistémico (les)
ZA201602148B (en) Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use
EP3197466A4 (en) A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation
NZ727749A (en) Use of anti-aging glycopeptides to enhance beta cell health, survival and improve transplant outcome
HK1232250A1 (zh) 製備用於人成纖維細胞和角質細胞溶液的噴霧式細胞化合物的方法及其作為皮膚損傷中的再生劑的用途